脓毒性休克患者对高与低平均动脉压目标反应的异质性:一项随机对照试验的事后分析
该研究为SEPSIS-PAM随机对照试验的事后分析,纳入776例脓毒性休克患者,比较平均动脉压65-70 mmHg与80-85 mmHg两个目标。主要终点28天死亡率无显著治疗效应异质性(sweep p值=0.664;95%CI 0.633-0.673)。在将24小时中介变量控制在对照水平时,较高平均动脉压目标对死亡率的直接效应不显著(RD=0.017;95%CI -0.052至0.086;p=0.62)。但若达到较高平均动脉压需要大剂量去甲肾上腺素和/或24小时皮肤花斑未消退,则通过那些中介变量传递的效应与死亡率升高相关(风险差分别为0.027;95%CI 0.012-0.047和0.012;95%CI 0.001-0.026)。结论提示脓毒性休克对不同血压目标无反应异质性,但当需要大剂量去甲肾上腺素或存在皮肤花斑时,追求较高平均动脉压目标可能有害。
要点
- 脓毒性休克患者对不同平均动脉压目标(65-70 mmHg vs 80-85 mmHg)的28天死亡率无显著治疗效应异质性(sweep p值=0.664;95%CI 0.633-0.673)。
- 将24小时中介变量控制在对照水平时,较高平均动脉压目标对死亡率的直接效应不显著(RD=0.017;95%CI -0.052至0.086;p=0.62)。
- 若达到较高平均动脉压需要大剂量去甲肾上腺素,通过该中介变量传递的效应与死亡率升高相关(风险差=0.027;95%CI 0.012-0.047)。
- 若24小时皮肤花斑未消退,通过该中介变量传递的效应与死亡率升高相关(风险差=0.012;95%CI 0.001-0.026)。
适用人群与场景
- 脓毒性休克患者,纳入SEPSIS-PAM随机对照试验并进行分析的776例患者。
红旗征与不能漏的情况
- 达到较高平均动脉压目标需要大剂量去甲肾上腺素时,通过该中介变量传递的效应与死亡率升高相关(风险差=0.027;95%CI 0.012-0.047)。
- 24小时皮肤花斑未消退时,通过该中介变量传递的效应与死亡率升高相关(风险差=0.012;95%CI 0.001-0.026)。
研究设计与关键结果
- 研究类型:SEPSIS-PAM多中心实用随机对照试验的事后分析;样本量776例;人群为脓毒性休克患者;干预为平均动脉压目标80-85 mmHg vs 65-70 mmHg。
- 主要终点28天死亡率无显著治疗效应异质性(sweep p值=0.664;95%CI 0.633-0.673)。
- 将24小时中介变量(平均动脉压演变、去甲肾上腺素需求、乳酸、花斑评分、尿量)控制在对照水平时,较高平均动脉压目标对死亡率的直接效应不显著(RD=0.017;95%CI -0.052至0.086;p=0.62)。
- 若达到较高平均动脉压需要大剂量去甲肾上腺素,通过该中介变量传递的效应与死亡率升高相关(风险差=0.027;95%CI 0.012-0.047)。
- 若24小时皮肤花斑未消退,通过该中介变量传递的效应与死亡率升高相关(风险差=0.012;95%CI 0.001-0.026)。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒性休克对不同血压目标无反应异质性;当达到较高平均动脉压目标需要大剂量去甲肾上腺素或存在皮肤花斑时,追求较高平均动脉压目标可能有害。
指南或共识出处
- SEPSISPAM(ClinicalTrials.gov编号NCT01149278)随机对照试验的事后分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The best blood pressure target in sepsis is a matter of debate. SEPSIS-PAM, a large multicenter pragmatic randomized controlled trial, compared two mean arterial pressure targets (65-70 mmHg vs 80-85 mmHg) in septic shock and did not find any difference in mortality. The goal of this study was to assess whether (i) heterogeneity of treatment effect (HTE) exists in the response to different targets and (ii) the initial clinical trajectory can inform the optimal blood pressure target.
METHODS: The primary outcome was mortality at day 28. Secondary outcomes included mortality at day 90, acute kidney injury (AKI), and severe AKI based on the KDIGO classification, need for renal replacement therapy, renal replacement therapy, and vasopressor-free days. The presence of HTE was tested for and, if present, quantified. The interaction between post-randomization evolution of the MAP, norepinephrine requirements, lactate, mottling score, and urine output was estimated using a multimediation analysis.
RESULTS: 776 patients were enrolled and analyzed in this study. There was no evidence of significant treatment effect heterogeneity based on baseline characteristics (sweep p-value = 0.664; 95% CI: 0.633-0.673). The direct effect of a higher MAP target on mortality, holding 24 h mediators at their control-level values, was not significant (RD = 0.017; 95% CI - 0.052 to 0.086; p = 0.62). However, if reaching a higher MAP required high norepinephrine doses and/or did not result in mottled skin resolution at 24 h, the effect transmitted through those mediators was associated with higher mortality (risk difference = 0.027; 95% CI 0.012-0.047 and 0.012; 95% CI 0.001-0.026).
CONCLUSION: Our results suggest the absence of heterogeneity of the response to different blood pressure targets in patients with septic shock. Targeting a higher MAP target may be associated with harm when high norepinephrine doses are required or when mottled skin is present.
TRIAL REGISTRATION: SEPSISPAM ClinicalTrials.gov number, NCT01149278.
参考来源
- Pirracchio R, Fong N, Legrand M, et al. Heterogeneity in the response to a high vs low mean arterial pressure target in patients with septic shock a post hoc analysis of a randomized controlled trial. Intensive Care Med. 2025. PMID: 40960603. doi:10.1007/s00134-025-08104-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。